Table 2. Association of baseline ctDNA detectability with clinicopathological features.
| Detectable cthNA (n = 23) |
Undetectable cthNA (n = 30) |
||
|---|---|---|---|
| Age (years) | |||
| Median (range) | 71 (27–90) | 61.5 (31–85) | P = 0.389 |
| Sex | |||
| Female | 7 (30.4%) | 17 (56.7%) | P = 0.057 |
| Male | 16 (69,6) | 13 (43,3) | |
| Stage | |||
| III non-resectable | 3 (13.0%) | 8 (26.7%) | P = 0.225 |
| IV | 20 (87.0%) | 22 (73.3%) | |
| Somatic mutation | |||
| BRAF (codon 600) | 11 (47.8%) | 13 (43.3%) | P = 0.745 |
| NRAS (exon 2 or 3) | 12 (52.2%) | 17 (56.7%) | |
| Tumor thickness (mm) | |||
| Mean ± SD | 3.51 ± 2.69 | 2,80 ± 1.91 | P = 0.409 |
| Ulceration | |||
| No | 7 (30.4%) | 14 (46.6%) | P = 0.458 |
| Yes | 7 (30.4%) | 8 (26.7%) | |
| Unknown | 9 (39.2%) | 8 (26.7%) | |
| Treatment | |||
| Nivolumab | 21 (91.3%) | 28 (93.3%) | P = 0.657 |
| Nivo + Ipilimumab | 2 (8.7%) | 2 (6.7%) | |
| Previous treatment | |||
| None (1st line) | 12 (52.2%) | 14 (46.7%) | P = 0.230 |
| Chemotherapy | 1 (4.3%) | 1 (3.3%) | |
| Immunotherapy | 0 (0%) | 5 (16.7%) | |
| Targeted therapy | 10 (43.5%) | 10 (33.3%) | |
| Number of metastatic sites | |||
| Mean ± SD | 4,7 ± 2,0 | 4,7 ± 4,1 | P = 0.186 |
| Baseline LDH (UI/L) | |||
| Mean ± SD | 321 ± 304 | 180 ± 61 | P = 0.070 |
| Response group | |||
| OR+ | 6 (26.1%) | 13 (43.3%) | P = 0.337 |
| OR-PD+ | 11 (47.8%) | 9 (30.0%) | |
| OR-PD− | 6 (26.1%) | 8 (26.7%) | |